Study finds limited long-term mental health effects of psilocybin in mouse models

A multi-lab study across five Bay Area research centers investigated whether psilocybin could produce lasting improvements in anxiety and depression-like behaviors in mice, but found only modest and inconsistent results. The findings suggest that the drug’s therapeutic potential may not be as durable as previously hoped in animal models. Researchers caution against overestimating its immediate benefits without further long-term data.

A multi-lab study conducted across five research centers in the Bay Area examined the long-term mental health effects of psilocybin in mouse models, focusing on anxiety and depression-like behaviors. The investigation found only modest and inconsistent improvements in these behavioral markers over time, suggesting that any therapeutic benefits observed may not be durable. While earlier studies had indicated promising short-term effects of psychedelics like psilocybin in both animal and human trials, this new research highlights a gap between initial optimism and sustained outcomes in preclinical models. The findings underscore the need for caution in interpreting early results and emphasize that long-term data remain insufficient to confirm lasting mental health benefits.

The study builds on growing interest in psychedelic-assisted therapies, particularly following recent clinical trials showing rapid antidepressant effects in humans. However, this animal research suggests that translating short-term improvements into enduring outcomes may be more complex than previously assumed. The participating institutions—though unnamed—represent a collaborative effort to rigorously assess psilocybin’s potential beyond initial enthusiasm. Researchers involved are urging the scientific community not to overestimate immediate benefits without further longitudinal data. What remains unclear is whether these findings will influence regulatory decisions, clinical trial design, or public perc